screening or as a by-product of an unrelated medical or surgical procedure, significant numbers of cases are diagnosed as a result of a search for an underlying cause. Little is known, however, about the medical care resources devoted to diagnosing and treating cancer-related symptoms before a definitive cancer diagnosis. Previous research using SEER-Medicare data to measure incremental costs and utilization associated with cancer started with the date of diagnosis. [1] [2] [3] [4] We hypothesized that health care use increases before diagnosis of a new primary cancer for these reasons: (1) signs and symptoms may motivate patients to seek symptom alleviation and diagnosis of the underlying disease, which ultimately is discovered to be cancer or, alternatively, an indolent tumor is diagnosed because the physician was searching for something else; (2) misdiagnosis that leads to a diagnostic work-up, selection of an incorrect diagnosis, a treatment attempt, treatment failure, rediagnosis, and so on, until the cancer is found; (3) patients seek alleviation of symptoms, but do not elect to pursue the path of confirming a cancer diagnosis, leading to a delayed diagnosis; (4) the primary focus of diagnosis and treatment may mask a cancer and delay diagnosis; (5) delay in assigning a cancer diagnosis due to existential factors of everyday life may cause delays of weeks or months while the diagnostic evidence is accrued; and (6) older patients are more likely to have multiple chronic diseases that may mask cancer symptoms, leading to a longer and more service-intensive pattern of utilization leading up to their cancer diagnoses.
To test these hypotheses, we accessed the informatics resources of the Cancer Research Network (CRN), a consortium of group-model health maintenance organizations with comprehensive administrative and electronic medical record information for the populations they serve. The CRN represents a highly suitable laboratory for this research as a result of the defined, stable populations of cancer patients.
This study uses a case-control design and data from 4 CRN health plans over a 9-year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . We used these data to estimate the incremental medical care use among adult cancer patients, relative to cancer-free persons, aged 18 and older, for the prediagnosis phase of care. We define this period as the 12 months before the month of cancer diagnosis. Measures of utilization included inpatient stays and days of care, ambulatory doctor office visits, emergency department visits, same-day surgical procedures, medication dispensings, imaging procedures, and laboratory tests.
METHODS

Research Setting
This research was conducted within 4 nonprofit integrated health care systems that are members of the CRN: Group Health Cooperative (based in Seattle, WA); the Henry Ford Health System (based in Detroit, MI); and the Northwest (based in Portland, OR) and Colorado regions of Kaiser Permanente (based in Denver, CO). Each of these systems provides comprehensive health care to defined populations through closed-panel delivery models with salaried physicians. These systems also have tumor registries and integrated electronic medical record systems. Each organization provides private and public health insurance coverage, including Medicare Advantage and Medicaid risk contracts, resulting in diverse enrollments that generally represent their local communities. 5, 6 The Institutional Review Boards of the 4 participating organizations approved this project.
Research Design and Study Population
We used a longitudinal case-control design to calculate the incremental medical care resource used to diagnose cancer. We defined cases as those patients enrolled in 1 of the 4 participating health plans between January 1, 2000 and December 31, 2008 with evidence of Z1 primary tumors. These patients had at least 30 days of continuous health plan eligibility during this 9-year period. We excluded utilization data on individuals whose cancers were diagnosed before their 18th birthdays, but included their data from their 18th birthdays onward. We randomly selected control patients from health plan members with no evidence of cancer before January 1, 2009. Controls were frequency matched on a 5:1 ratio to cases by age group, sex, and health plan eligibility. Pseudo-diagnosis dates were assigned to controls as the date of cancer diagnosis from their matched case. We defined 4 subgroups for the current analyses: cancer patients aged 65 years and older at time of cancer diagnosis; cancer patients aged below 65 years at time of diagnosis; control patients aged 65 years and older as of the date of diagnosis for the matching cancer case; and control patients aged below 65 years as of the date of diagnosis for the matching cancer case. Enrollment gaps of r95 days were presumed to be unintended administrative changes and were not considered when calculating continuous enrollment.
Data
Data on cancer diagnoses, including diagnosis date, were extracted from accredited tumor registries for January 1, 2000 through December 31, 2008. Data on health plan eligibility were extracted from enrollment files. We extracted comprehensive utilization data for all study cases and controls for 2000 to 2008 from electronic data warehouses maintained by the participating organizations. These data warehouses compile information from EMRs, hospital discharge abstracts, claims, hospital, emergency room, sameday surgical, and medical office ambulatory care encounters, and outpatient dispensings. All persons included in the samples had coverage of ambulatory prescription medications, including Medicare Advantage enrollees. We extracted race and ethnicity for cancer patients from tumor registries. For controls, this information was extracted from health plan enrollment files and hospital discharge abstracts. Data were standardized across plans according to specifications established by the CRN's Virtual Data Warehouse. 7
Measures
We computed 8 different monthly utilization rates: short-term hospital admissions, total inpatient days, emergency department encounters, same-day surgical procedures, ambulatory medical office encounters, outpatient imaging procedures, outpatient laboratory procedures, and outpatient medication dispensings. Hospital admissions and days were counted as of the date of admission, including stays over 31 days. Medication dispensings, including refills, were counted as of the fill date (regardless of the number of days supplied). We counted all other care receipt on the day it occurred.
Analysis
The month of cancer diagnosis was set as the index point for cases. We assigned a pseudo date to controls to allow us to track utilization rates over the months before and after the cancer diagnosis. In this analysis, we present data for the 12 months before the month of diagnosis recorded in tumor registries. The numbers of cases and controls varied somewhat across the months of the prediagnosis phase because of differences among patients in health plan eligibility relative to the timing of diagnosis.
To determine the statistical significance of the observed differences, we computed w 2 tests on categorical variables and t tests on the differences of means for monthly utilization rates between cancer cases and matched controls, and between aged and nonaged patients. We conducted analyses for the entire population of cases and controls.
RESULTS
We identified 121,293 cancer cases and 522,839 controls ( Table 1 ). The average age of cancer patients was about 60.7 years, compared with 58.5 years for controls. Twentyone percent (N = 24,966) of cancer patients were aged 75 years and older, compared with 17% of controls (N = 91,370). The sex distributions between cancer cases and controls were similar: 57% (N = 69,106) of cancer patients were female, compared with 61% (N = 319,997) for controls. The differences in race/ethnicity distributions were a function of different data sources for each group-tumor registry versus health plan enrollment files. About 69% (N = 76,527) of cancer cases were incident during the study period. The remaining 44,766 cases were prevalent at the beginning of the study period. Breast cancers accounted for 20% of the cases (N = 24,684), followed by prostate cancers (14% of cases, N = 16,648) and other female genital cancers at (12% of cases, N = 14,619). Colorectal cancers accounted for 9% of the cases (N = 10,409), and lung cancers represented 8% of cases (N = 9,229).
Hospital discharge rates before diagnosis for aged and nonaged cases were at the same levels as their respective controls at the beginning of the observation period-14 discharges per 1000 members for aged patients and about 8 discharges per 1000 members for nonaged patients (Fig. 1A) .
During the fourth month before cancer diagnosis, however, discharge rates for aged cases increased dramatically when compared with aged controls (41 discharges per 1000). This rate was 2-fold higher than aged controls for the month before diagnosis. Discharge rates for nonaged cases rose sharply during the last 3 months of the observation period when compared with aged cases (20 discharges per 1000 members), whereas rates for controls were unchanged across the year. Discharge rates for aged cases and controls were consistently higher than nonaged cases and controls, respectively. Rates of hospital days used per month and dis-charges followed similar patterns over the year (Fig. 1B) . During the month before diagnosis, aged cancer patients used 200 hospital days per 1000 members (compared with 85/1000 for aged controls) and nonaged cancer patients used 105 hospital days per 1000 members (compared with 30/ 1000 for nonaged controls). Emergency department visit rates for aged cancer patients were 78 visits per 1000 members for the month before cancer diagnosis, compared with 38 visits per 1000 members for aged controls, and 63 visits per 1000 members versus 24 visits per 1000 members for nonaged cases and controls, respectively (Fig. 1C) . Same-day surgical procedure rates increased significantly during the 3 months before diagnosis for both aged and nonaged cancer cases, with rates for aged patients remaining consistently higher than nonaged patients ( Fig. 2A ). Use of same-day surgical procedures by controls remained relatively constant throughout the year. Rates of medical office visits (Fig. 2B) , imaging procedures (Fig. 2C) , laboratory tests (Fig. 3A) , and prescription dispensing (Fig. 3B ) all climbed sharply for cases 4 to 12 months before diagnosis, compared with controls, and aged patients had consistently higher utilization rates than nonaged patients (to view larger color ver- All utilization differences for both aged and nonaged cases versus controls were statistically significant for at least the 2 months before cancer diagnosis. Twelve of 16 differences were statistically significant during the third month before diagnosis. For ambulatory office visits, laboratory tests, and dispensings, cancer cases have significantly higher utilization rates than controls over the entire year before diagnosis. The differences in monthly mean utilization rates per 1000 persons by service type and age group for the prediagnosis phase and their statistical significances are shown in Table 2 .
CONCLUSIONS AND FUTURE RESEARCH
This study confirmed our hypothesis that health care utilization increases before a patient is diagnosed with cancer. We found that patients had multifold increases in use of inpatient, ambulatory, emergency department, imaging, laboratory, and pharmacy services during the months leading up to a cancer diagnosis, compared with a matched noncancer control group, and this held true for both aged and nonaged cancer patients. These findings indicate that all cancer-related care does not start from the diagnosis date, and both cancer research and care should account for this fact.
In addition to confirming the surge in health care use before diagnosis, this study also highlights areas in need of future research to further articulate this phenomenon. This research should address questions, such as:
What accounts for this ramp-up in utilization rates before diagnosis? Why do patients aged 65 years and older have such markedly higher utilization rates compared with patients below 65? What portion of this utilization is the result of delayed recognition of cancer? What portion of this utilization is the result of rigorous accrual criteria for new primary tumors for cancer registries? How much of this utilization is the result of patient and/or provider resistance to rapid diagnostic work-ups? Answering these questions will help shape future research in this area and will illuminate our understanding of this important, yet understudied, phase of cancer care. In addition to issues of cost and utilization, the search for a cancer diagnosis is a complex, difficult, and frustrating experience for patients. As such, more research should examine whether this research could help shorten this period. This Brief Report presents a preliminary view of a 4-site, 9-year comprehensive database on cancer patients and frequency-matched controls. Future publications from this research team will address how medical care costs of cancer differ between health maintenance organizations and Medicare indemnity coverage, as well as whether cancers occurring before age 65 have continued cost effects after age 65.
